MelBas Therapeutics
MelBas Therapeutics is a preclinical-stage biopharmaceutical company developing a targeted small-molecule therapy designed to disrupt key oncogenic signaling pathways that drive tumor survival and metastasis. The lead candidate has demonstrated anti-tumor and anti-metastatic activity in multiple solid tumor models, including pancreatic, ovarian, and breast cancers, and is being advanced toward IND-enabling studies.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
Funding
Founders
Founder details are not available yet.
Product
Problem
Cancers such as pancreatic, ovarian, and breast tumors remain exceptionally difficult to treat due to aggressive metastasis, therapy resistance, and a lack of durable responses to existing agents. These challenges leave patients with limited options once standard-of-care treatments fail, driving a pressing need for therapies that target novel disease-driving mechanisms.
Solution
MelBas is advancing a therapeutic candidate designed to disrupt key signaling pathways that enable tumor survival and spread. The company's lead program employs a targeted small-molecule approach intended to selectively inhibit cancer-driving processes while sparing normal tissue. Preclinical data support the compound's ability to reduce tumor burden and limit metastatic progression in multiple solid tumor models. The company is working toward Investigational New Drug (IND)-enabling studies and clinical translation for patients with high unmet need.
Target Audience
Primary stakeholders are oncologists, clinical trial sites, and patients with advanced or metastatic solid tumors, particularly those with limited alternatives after standard therapies.
Features
- Lead candidate targets a distinct oncogenic pathway not addressed by currently approved therapies
- Designed for oral administration to support convenient outpatient dosing
- Demonstrated anti-tumor and anti-metastatic activity in preclinical solid tumor models
- Focused on multiple aggressive cancer types, including pancreatic, ovarian, and breast cancers
- Clinical development plan is oriented toward biomarker-selected patient populations to maximize therapeutic index